<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6047">
  <stage>Registered</stage>
  <submitdate>6/11/2015</submitdate>
  <approvaldate>6/11/2015</approvaldate>
  <nctid>NCT02601378</nctid>
  <trial_identification>
    <studytitle>A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.</studytitle>
    <scientifictitle>A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CLXS196X2101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Uveal Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LXS196

Experimental: LXS196 - About 78 patients will be enrolled in dose expansion


Treatment: drugs: LXS196


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of dose limiting toxicities (DLTs) (Dose escalation only) - cycle = 28 days</outcome>
      <timepoint>Cycle 1 in dose escalation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence and severity of adverse events and serious adverse events, including changes in laboratory parameters, vital signs and ECGs graded as per NCI CTCAE version 4.03 (All patients)</outcome>
      <timepoint>Continuously throughout the study until 30 days after treatment discontinuation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose interruptions, reductions and dose intensity</outcome>
      <timepoint>Continuously throughout the study until 30 days after treatment discontinuation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate (ORR) per RECIST version 1.1 criteria</outcome>
      <timepoint>From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma LXS196 concentration-time profiles</outcome>
      <timepoint>Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Modulation of signaling molecules downstream of protein kinase C inhibitor</outcome>
      <timepoint>Baseline and Cycle 1 Day 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival (PFS) per RECIST version 1.1 criteria</outcome>
      <timepoint>From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PK parameters of LXS196:AUC</outcome>
      <timepoint>Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PK parameters of LXS196: Cmax</outcome>
      <timepoint>Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PK parameters of LXS196: Tmax</outcome>
      <timepoint>Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PK parameters of LXS196: t1/2</outcome>
      <timepoint>Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma PK parameters of LXS196: Racc</outcome>
      <timepoint>Cycle 1 Day 1, 2, 3, 15; Cycle 2, 3, 4, 5 and 6 Day1</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Metastatic uveal melanoma (histologically or cytologically confirmed) that is judged
             to be progressive

          -  Willingness to provide newly obtained tumor tissue at baseline and on treatment unless
             contraindicated by medical risk

          -  Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension (longest diameter to be recorded) as &gt; 20 mm with conventional
             techniques or as &gt;10 mm with CT scan.

          -  ECOG performance status = 1

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Malignant disease other than that being treated in this study

          -  Symptomatic or untreated leptomeningeal or brain metastases or spinal cord
             compression. Treated brain metastases must have been stable for at least 1 month.

          -  Impaired cardiac function or clinically significant cardiac diseases

          -  Patients who are receiving treatment with medications that cannot be discontinued
             prior to study entry and that are considered to be any of the following:

          -  known and possible risk for QT prolongation

          -  known to be strong inducers or inhibitors of CYP3A4/5

          -  known to be inducers or inhibitors of P-gp

          -  known to be substrates of CYP3A4/5 and P-gp with a narrow therapeutic index

          -  Patients with abnormal laboratory values as defined by the protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>24/03/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Novartis Investigative Site - Westmead</hospital>
    <postcode>2145 - Westmead</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to characterize the safety, tolerability, pharmacokinetics (PK),
      pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent in
      patients with metastatic uveal melanoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02601378</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address />
      <phone>1-888-669-6682</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>